Evidence map›Paper›PMID 41860109›Full record

ArticleActa paediatrica (Oslo, Norway : 1992)2026

Patent Ductus Arteriosus Persistence and Neurodevelopmental Outcomes: A Restrictive Treatment Approach Does Not Compromise Neurological Development.

Moses Kallenberger, Alina Bartling, Britta Hüning, Monia Vanessa Dewan, Johanna Bialas, Lisa Middendorf, Anne-Kathrin Dathe, Ursula Felderhoff-Müser, Anja Stein

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta paediatrica (Oslo, Norway : 1992), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Moses KallenbergerDepartment of Pediatrics I, Neonatology, Pediatric Intensive Care, Pediatric Infectiology and Pediatric Neurology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Alina BartlingDepartment of Pediatrics I, Neonatology, Pediatric Intensive Care, Pediatric Infectiology and Pediatric Neurology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Britta HüningDepartment of Pediatrics I, Neonatology, Pediatric Intensive Care, Pediatric Infectiology and Pediatric Neurology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.ORCID https://orcid.org/0000-0002-6815-5573
Monia Vanessa DewanDepartment of Pediatrics I, Neonatology, Pediatric Intensive Care, Pediatric Infectiology and Pediatric Neurology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Johanna BialasDepartment of Pediatrics I, Neonatology, Pediatric Intensive Care, Pediatric Infectiology and Pediatric Neurology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Lisa MiddendorfDepartment of Pediatrics I, Neonatology, Pediatric Intensive Care, Pediatric Infectiology and Pediatric Neurology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Anne-Kathrin DatheDepartment of Pediatrics I, Neonatology, Pediatric Intensive Care, Pediatric Infectiology and Pediatric Neurology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Ursula Felderhoff-MüserDepartment of Pediatrics I, Neonatology, Pediatric Intensive Care, Pediatric Infectiology and Pediatric Neurology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Anja SteinDepartment of Pediatrics I, Neonatology, Pediatric Intensive Care, Pediatric Infectiology and Pediatric Neurology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimOptimal treatment strategies for patent ductus arteriosus (PDA) and their impact on neurodevelopmental outcomes remain controversial. This study investigates the influence of PDA duration on neurodevelopment under a restrictive treatment approach.

methodsRetrospective single-center study of 171 preterm infants ≤ 32 weeks gestation with echocardiographically-identified PDA (treated hemodynamically significant PDA-hsPDA, untreated PDA-ntPDA) or no PDA. Assessments included cerebral MRI at term-equivalent age, General Movement Assessment at 8-16 weeks and Bayley Scales of Infant Development III at 22-26 months corrected age. Infants with severe IVH ≥ III° were excluded a priori to isolate PDA effects without major brain injury.

resultsThe hsPDA group represented infants with lower gestational age and birth weight, higher rates of bronchopulmonary dysplasia and longer hospitalization (all p < 0.001). Transcerebellar diameter differed significantly between groups (p = 0.004). PDA duration showed a statistical association with MRI-detected IVH ≤ II° in the hsPDA subgroup (OR 1.01 per day, p = 0.05). Multivariate analysis did not confirm any significant impact of PDA group or duration on neurodevelopmental outcomes after adjusting for confounders.

conclusionGestational age and comorbidities, rather than longer PDA duration, determined neurodevelopmental outcomes in our cohort of very preterm infants without severe brain injury.

Indexed as

Ductus Arteriosus, PatentNeurodevelopmentNeurodevelopmental DisordersFemaleHumansInfantInfant, NewbornInfant, PrematureMagnetic Resonance ImagingMaleRetrospective Studiesgeneral movement assessmentmagnetic resonance imagingneurodevelopmentpatent ductus arteriosustranscerebellar diameter

Identifiers

PMID41860109
PMCPMC13250968

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.